



P/3610-70

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Pierre-Yves COQUERON et al.

Serial No.: 10/583,011

Filed: October 6, 2006



Date: January 11, 2008

Group Art Unit: 1625

Examiner: Morris, Patricia L.

For: 2-PYRIDINYLETHYLCARBOXAMIDE DERIVATIVES AND THEIR USE
AS FUNGICIDES

TERMINAL DISCLAIMER

Mail Stop Amendment- FEE
Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

This is a terminal disclaimer under Rule 321 (c) to obviate a nonstatutory double-patenting rejection over a co-pending application, which is being filed in response to an office action of October 31, 2007, in reference to the above-identified patent application.

Application Number 10/545,364 is assigned to Bayer Cropscience S.A., a corporation organized under the laws of France, having its principal place of business at 16 rue Jean-Marie Leclair, F-69009 Lyon France. Bayer Cropscience S.A. thus holds a 100 percent interest in both the above-identified application and Application No. 10/545,364, and disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term, defined in 35 U.S.C. §§ 154, 156, and 173 as shortened by any terminal disclaimer filed prior to the grant,

Terminal Disclaimer
Coqueron et al.
Appl. No. 10/583,011

of any patent or patents granted on said Application No. 10/545,364. The owner agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent or patents granted on said Application No. 10/545,364 are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors, or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term, as defined in 35 U.S.C. §§ 145 to 156 and 173, of any patent or patents granted on said Application No. 10/545,364, as shortened by any terminal disclaimer filed prior to its patent grant, in the event that such patent(s): (1) expire(s) for failure to pay a maintenance fee, (2) is (are) held unenforceable, (3) is (are) found invalid by a court of competent jurisdiction, (4) is (are) statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §§ 1.321, (5) has (have) all claims cancelled by a re-examination certificate, (6) is (are) reissued, or (7) is (are) in any manner terminated prior to the expiration of its full statutory term as shortened by any terminal disclaimer filed prior to its (their) grant.

For submissions on behalf of an organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the organization.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements and the like so made

Terminal Disclaimer
Coqueron et al.
Appl. No. 10/583,011

are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that any such willful false statement may jeopardize the validity of the application of any patent issued thereon.

The fee of \$130 for a terminal disclaimer under 37 C.F.R. § 1.20(d) is requested to be charged to Deposit Account No. 15-0700. A duplicate copy of this page is enclosed.

Respectfully submitted,

7 Jan 2008

Date

Paul Grandinetti
Reg. No. 30,754
counsel for Applicants